secwatch / observer
8-K filed May 21, 2026, 4:15 PM ET ticker SRBK CIK 0001951276
other material confidence high sentiment positive materiality 0.60

SR Bancorp authorizes third stock repurchase program for up to 10% of outstanding shares (801,320 shares)

SR Bancorp, Inc.

Machine-readable event card

schema_version
secwatch.filing_event.v1
accession
0000943374-26-000207
form_type
8-K
ticker
SRBK
cik
0001951276
company_name
SR Bancorp, Inc.
filed_at
2026-05-21T20:15:27+00:00
discovered_at
2026-05-21T20:17:00.353051+00:00
generated_at
2026-05-21T22:04:13.510830+00:00
sec_items
["8.01", "9.01"]
event_type
other_material
sentiment
positive
materiality_score
0.6
calibrated_materiality_score
0.6
confidence
high
secwatch_canonical_url
https://secwatch.observer/filing/0000943374-26-000207
json_url
https://secwatch.observer/filing/0000943374-26-000207.json
markdown_url
https://secwatch.observer/filing/0000943374-26-000207.md
text_url
https://secwatch.observer/filing/0000943374-26-000207.txt
edgar_index_url
https://www.sec.gov/Archives/edgar/data/1951276/000094337426000207/0000943374-26-000207-index.htm
edgar_primary_document_url
https://www.sec.gov/Archives/edgar/data/1951276/000094337426000207/form8k_052126.htm
generated_by_model
deepseek-v4-flash:cloud@v2
review_status
machine_generated
human_reviewed
false
corrected
false
correction_note
null
correction_timestamp
null
superseded_by
null

Comparable filings

EMYB

Embassy Bancorp expands stock repurchase program by additional $5M

Embassy Bancorp, Inc. June 1, 2026, 4:37 PM ET other_material Items 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

XAIR

Beyond Air receives Nasdaq panel grant for continued listing; must meet bid price rule by July 31, 2026

Beyond Air, Inc. June 1, 2026, 4:30 PM ET other_material Items 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

CTXR

Citius Oncology reports Phase 1 combo data: 24% ORR, 33% in endometrial cancer; Phase 2 planned

Citius Pharmaceuticals, Inc. June 1, 2026, 4:30 PM ET other_material Items 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

CTOR

Citius Oncology reports Phase 1 combo data for LYMPHIR in gynecologic cancers; 24% ORR, 33% in endometrial cancer

CITIUS ONCOLOGY, INC. June 1, 2026, 4:30 PM ET other_material Items 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

SYRE

Spyre Therapeutics expands SPY003 license field beyond IBD with dosing restrictions until 2028-2030

Spyre Therapeutics, Inc. June 1, 2026, 4:01 PM ET other_material Items 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

ORKA

Oruka Therapeutics expands ORKA-001 license to include IBD; clinical dosing restrictions until 2028-2030

Oruka Therapeutics, Inc. June 1, 2026, 4:01 PM ET other_material Items 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

VIASP

Via Renewables to redeem all 1,884,935 shares of its 8.75% Series A Preferred at $25.00 per share plus dividends

Via Renewables, Inc. June 1, 2026, 3:06 PM ET other_material Items 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

BUKS

CEO Christopher Reedy discloses ongoing cancer treatment; remains in role

BUTLER NATIONAL CORP June 1, 2026, 12:41 PM ET other_material Items 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

Source: SEC EDGAR
accession 0000943374-26-000207

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.